The Hepatitis B Foundation calls upon all companies developing COVID-19 vaccines to include people living with hepatitis B and liver disease in their clinical trials, and to make the resulting sub-group data publicly available.
The inclusion of these groups in clinical trials will help improve access to approved vaccines, and will broaden trust and acceptance of the vaccines, especially among those who are unsure if they should receive any COVID-19 vaccine. We must account for groups who may be more susceptible to severe illness from the coronavirus.
Too often the medical community has neglected to listen to the concerns of underrepresented groups, and the consequences have been devastating. We must ensure that the voices of the 300 million people around the world who are living with hepatitis B are not forgotten.
Data is one of the most powerful tools we have to build vaccine confidence amongst vulnerable populations, and one we must fully utilize in order to earn the trust of concerned communities.
Questions? Email us: Contact Email